Clinical Stage

4 articles in this category

HealthcareBiotechnologyClinical-Stage

SELLAS Life Sciences (SLS) – Imminent Phase 3 Catalyst Drives Bullish Outlook

SELLAS Life Sciences Group (SLS) is positioned for a potential surge driven by the imminent topline data readout from the Phase 3 REGAL trial of galinpepimut-S in AML. The stock surged 12% on July 17, 2026, in anticipation of this company-defining catalyst. With the 80th event likely days away, the binary outcome makes a 5-day horizon most appropriate. Analyst consensus is Strong Buy with a $27.50 average target, and the company has a strong cash position ($71.8M) to fund operations. High beta (2.42) amplifies both upside and downside risk.

Jul 17, 2026SLS

Stock Weather AIBiotechnologyClinical Stage

Edgewise Therapeutics – 2025-12-19 - Increase Confidence 7/10

Strong cash reserves and advancing clinical pipeline signal near-term upside despite ongoing losses; Q4 data readouts act as catalyst.

Dec 19, 2025EWTX

Stock Weather AIBiotechnologyClinical Stage

Vera Therapeutics – 2025-12-02 - Increase Confidence 8/10

Strong cash position and recent BLA submission for atacicept, combined with positive Phase 3 data, signal near-term upside despite negative free cash flow.

Dec 2, 2025VERA

Stock Weather AIBiotechnologyClinical Stage

Vera Therapeutics – 2025-11-27 - Increase Confidence 8/10

Positive Phase 3 trial data and imminent BLA submission converge with strong institutional backing, signaling near-term upside for VERA.

Nov 27, 2025VERA